Abstract
Alcoholism is an increasing problem all over the world, and nowadays especially amongst teenagers. Although several drug treatments have been proposed for this condition, only a few have demonstrated a significant efficacy. Nalmefene, a novel compound that combines opioids mu-receptors antagonism and kappa-receptors partial agonism, was recently approved by the European Medicine Agency for the treatment of alcoholism. This drug can be very helpful in reducing the alcohol intake, and, as such, it can be considered one of the first and fundamental steps towards alcohol abstinence. The aim of this review is to discuss and comment on the available literature on nalmefene, as well as on novel treatment strategies of this condition (and perhaps of other addictions) opened by this latest pharmacological approach.
Keywords: Alcoholism, pharmacological treatments, nalmefene, opioids, reward system.
Current Medicinal Chemistry
Title:Nalmefene: A Novel Drug for an Old Disorder
Volume: 22 Issue: 27
Author(s): Donatella Marazziti, Silvio Presta, Stefano Baroni, Francesco Mungai, Armando Piccinni, Federico Mucci and Liliana Dell'Osso
Affiliation:
Keywords: Alcoholism, pharmacological treatments, nalmefene, opioids, reward system.
Abstract: Alcoholism is an increasing problem all over the world, and nowadays especially amongst teenagers. Although several drug treatments have been proposed for this condition, only a few have demonstrated a significant efficacy. Nalmefene, a novel compound that combines opioids mu-receptors antagonism and kappa-receptors partial agonism, was recently approved by the European Medicine Agency for the treatment of alcoholism. This drug can be very helpful in reducing the alcohol intake, and, as such, it can be considered one of the first and fundamental steps towards alcohol abstinence. The aim of this review is to discuss and comment on the available literature on nalmefene, as well as on novel treatment strategies of this condition (and perhaps of other addictions) opened by this latest pharmacological approach.
Export Options
About this article
Cite this article as:
Marazziti Donatella, Presta Silvio, Baroni Stefano, Mungai Francesco, Piccinni Armando, Mucci Federico and Dell'Osso Liliana, Nalmefene: A Novel Drug for an Old Disorder, Current Medicinal Chemistry 2015; 22 (27) . https://dx.doi.org/10.2174/0929867322666150821100538
DOI https://dx.doi.org/10.2174/0929867322666150821100538 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aβ(1-42) Aggregates into Non-Toxic Amyloid Assemblies in the Presence of the Natural Polyphenol Oleuropein Aglycon
Current Alzheimer Research Causes of Secretion Retention: Patient Factors, Ventilation, Devices, Drugs
Current Respiratory Medicine Reviews The Modern Spectrum of Rhabdomyolysis: Drug Toxicity Revealed by Creatine Kinase Screening
Current Drug Safety Evolving Therapeutic Targets in Ischemic Stroke: A Concise Review
Current Drug Targets Subject Index to Volume 9
Current Pharmaceutical Design A Legend in Neuroscience (1948-2018) Dr. Stephen D. Skaper, Ph. D
CNS & Neurological Disorders - Drug Targets Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Current Drug Targets Recent Progress in Machine Learning-based Prediction of Peptide Activity for Drug Discovery
Current Topics in Medicinal Chemistry Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets Formulation Optimization and Biopharmaceutical Evaluation of Imatinib Mesylate Loaded β-cyclodextrin Nanosponges
Pharmaceutical Nanotechnology Turning the Clock Ahead: Potential Preclinical and Clinical Neuropharmacological Targets for Alcohol Dependence
Current Pharmaceutical Design Transglutaminase Activity as a Possible Therapeutical Target in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity
Current Alzheimer Research The Toxicogenetics of Antirretroviral Therapy: The Evil Inside
Current Medicinal Chemistry Nanodevices Based on Silicon Nanowires
Recent Patents on Nanotechnology Manoglanistara - Emotional Wellness Phases Prediction of Adolescent Female Students by using Brain Waves
Current Signal Transduction Therapy Comparison Among Aerobic Exercise and Other Types of Interventions to Treat Depression: A Systematic Review
CNS & Neurological Disorders - Drug Targets Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry Opioids in Neuropathic Pain
Current Pharmaceutical Design